We are live on ! Find out more
ARTL icon

Artelo Biosciences
ARTL

1 hedge funds and large institutions have $38K invested in Artelo Biosciences in 2019 Q4 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% less ownership

Funds ownership: 0% → 0% (-0%)

12% less capital invested

Capital invested by funds: $43K → $38K (-$5K)

67% less funds holding

Funds holding: 3 → 1 (-2)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
1
Holders Change
-2
Holders Change %
-66.67%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$8K
2
Goldman Sachs
Goldman Sachs
New York
-$3.06K
3
TRCT
Tower Research Capital (TRC)
New York
-$1K
Name Holding Trade Value Shares
Change 		Change in
Stake
Goldman Sachs
1
Goldman Sachs
New York
$38K -$3.06K -5 -9%
UBS Group
2
UBS Group
Switzerland
– -$8K -13 Closed
TRCT
3
Tower Research Capital (TRC)
New York
– -$1K -1 Closed

ARTL Hedge Fund Activity: Q4 2019 in Review

1 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Artelo Biosciences (ARTL) for Q4 2019, worth a combined $38K — down 12% from $43K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of ARTL and 0 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 0 added.

The largest seller was UBS Group, exiting entirely with an estimated $8K sold.

  • 1 institutional investor held Artelo Biosciences (ARTL) as of Q4 2019, down from 3 in Q3 2019.
  • Funds reported $38K of Artelo Biosciences stock for Q4 2019, down 12% quarter-over-quarter.
  • 0 funds opened new Artelo Biosciences positions in Q4 2019 and 2 closed out, a net change of -2 holders.
  • The largest Artelo Biosciences seller in Q4 2019 was UBS Group, an estimated $8K sold.

Based on aggregated 13F filings for Q4 2019.